+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 0 - 30Years
All Genders
ID06087341

Phase I Study of NKG2D-CAR Memory T Cell Therapy for Advanced Sarcoma in Children, Adolescents, and Young Adults

Led by Antonio Pérez Martínez · Updated on 2024-04-12

18

Participants Needed

1

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a Phase I clinical trial studying memory T cells engineered to express an NKG2D chimeric antigen receptor CAR in children, adolescents, and young adults with advanced sarcoma. Sarcomas are rare childhood cancers with poor survival rates in advanced or relapsed cases, and current treatments have limited effectiveness and cause significant side effects. This trial aims to assess the safety and potential clinical activity of this novel NKG2D-CAR T cell therapy, building on promising preclinical and compassionate use experiences. Participants will be assigned to one of two groups based on tumor accessibility. Arm A includes patients with tumors or metastases that are not accessible and who will receive intravenous infusions of NKG2D-CAR memory T cells. Arm B includes patients with accessible tumors or metastases and will receive both intravenous and intratumoral infusions of these engineered T cells. All patients undergo lymphodepleting chemotherapy before the infusions, and some may receive low-dose radiotherapy. The study uses a dose-escalation design to determine the maximum tolerated dose and dose-limiting toxicities. During the study, participants will be monitored closely for safety outcomes, including toxicities up to 28 days after the last infusion and response rates at day 60. Researchers will also track the persistence of NKG2D-CAR T cells in blood and tumor sites, immune markers, cytokine levels, and molecular profiles over a 12-month period. Biopsies and blood samples will be collected to analyze various immune and tumor characteristics. The study involves detailed assessments to understand treatment effects and long-term safety in this patient population.

CONDITIONS

Brief Title

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma

Research Team

A

Antonio Pérez Martínez

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here